KopranQ3 FY25

Kopran Q3 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹272.66P/E: 33.5Market Cap: ₹1.3K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

No

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Target to grow to around INR1,200 crores in the next 3 years through new products and volume increase.
  • Expect 10%-12% growth in API segment next year, and about 20% growth in the following year.
  • Consolidated sales growth expected around 15% for FY '26 and 20% for FY '27.
  • Expansion in CMO and CDMO projects to contribute significantly; aiming for over 50% of business from these in 2 years.
  • Increased market share in key products like Meropenem (around 20% contribution currently).
  • Capacity expansions underway at Panoli and Mahad plants to meet increasing demand, with Panoli expected to stabilize next year.
  • Moving towards higher-margin regulated market projects for sustainable growth and profitability.
  • Pricing pressure from Chinese competition is stabilizing, with volume growth helping offset price erosion.

See what Kopran management said on margin guidance — free account, 30 seconds.

Fundraise plans

No
- Kopran Limited has not taken any new term loans recently; the only existing term loan is related to the Panoli plant taken about 4 years ago, currently around INR10-12 crores. - The remaining debt is mostly working capital, which fluctuates with inventory cycles. - About 30% of the working capital limits remain unused, indicating no immediate need for additional borrowing. - There is no mention of any planned new fundraising through equity or debt in the conference call. - Capex and capacity expansions are being managed within existing financial resources, with no large capex expected in the next 1-2 years. - Any future capex or projects requiring funding will depend on demand and project fruition, but currently, there are no disclosed plans for new fundraising. Hence, Kopran currently has no announced plans for fresh fundraising through equity or debt.

See what Kopran management said on order book — free account, 30 seconds.

Capex plans

Yes
  • For the next 1 to 2 years, Kopran Limited does not foresee very large capex, except possibly for setting up vial filling for penems.
  • Existing capacity is considered sufficient to meet expected demand for the next 2 to 3 years.
  • In FY '23 and '24, capex was around INR 60 crores each year; capex is expected to significantly reduce in the next couple of years.
  • Additional capex may be needed if existing projects under consideration materialize and demand increases, requiring dedicated plants.
  • For formulation businesses, capex remains moderate, around INR 10 crores over 9 months.
  • The Panoli plant capex is largely completed; commercial production expected to start in Q1 FY '26.
  • The company is also investing in expanding capacities for growing products like Faropenem and CMO/CDMO projects, which have better margins.

Track Kopran — get its next earnings analysis in your feed

How does Kopran rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisKopran
Rev 3Mar 1

How does Kopran rank in Pharmaceuticals & Biotechnology?

Compare Kopran against every Pharmaceuticals & Biotechnology company (Q3 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →